Basic Science and Pathogenesis.

Background: Individuals with Down Syndrome (DS) exhibit a unique aging profile and have early-onset Alzheimer's Disease (AD) due to a triplication of the amyloid precursor protein (APP) gene on chromosome 21.

Method: Here, we present a study of a 73-year-old non-Hispanic White female with DS who underwent extensive clinical assessments for several decades. She had a cognitive and functional impairment consistent with DS and AD-like symptoms.

Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease.

Alzheimer's disease (AD) is the leading cause of dementia worldwide. Numerous biomarker studies have clearly demonstrated that AD has a long asymptomatic phase, with the development of pathology occurring at least 2 decades prior to the development of any symptoms. These pathological changes include a stepwise development of amyloid-β (Aβ) plaques, followed by tau neurofibrillary tangles and subsequently extensive neurodegeneration in the brain.